Indications:

As a mono or adjunctive therapy for partial seizures. As an adjunctive therapy for myoclonic and primary generalized tonic-clonic seizures.

Mode of Action:

The first representative of a new class of AED. Levetiracetam binds to SV2A (synaptic vesicle protein), which is believed to hamper nerve conduction across synapses.This mechanism of action places Levetiracetam in a new class of AED known as pyrrolidine anticonvulsants.